AR and posterior cortical atrophy: AR signaling inhibitors (ARSI) are now the standard of care for locally advanced12, recurrent13, nonmetastatic castration-resistant9,17,18, metastatic castration-sensitive14–16 and metastatic castration-resistant PCa (mCRPC)10,11.